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Sir: Severe lactic acidosis is a biochemical marker found in 
hypoxia, and in congenital disorders of gluconeogenesis, pyru- 
vate and NADH-oxidation. Many patients with these inherited 
defects die or show growth and psychomotor retardation be- 
cause standard treatment of these disorders is unsatisfactory 
[1]. Dichloroacetate (DCA) is known to inhibit the pyruvate 
dehydrogenase-specific kinase in various tissues and it has a 
lactate-lowering effect in patients with chronic congenital lactic 
acidosis [2, 4]. Here, we report the successful treatment of 
severe lactic acidosis associated with hypertrophic cardiomyo- 
pathy in a patient with muscle cytochrome c oxidase (COX) 
deficiency. 
The patient was born at term to non-consanguineous healthy 
parents (birth weight 2700g; Apgar scores 9 and 10 at 1 and 
5 rain). At the age of 1 month he was admitted to a local hospi- 
tal because of rapid respiration, feeding difficulty, weakness, 
and lack of ocular fixation. The liver was 5 cm below the costal 
margin and he had severe metabolic acidosis with elevated 
blood lactate (5.5 mmol/1). ECG showed signs of ischaemia 
and echocardiography showed marked hypertrophic ardio- 
myopathy. 
He was transferred to our department in a critical condition 
(polypnoic and dyspnoic) and a repeat ECG showed marked 
hypertrophy of the left ventricular posterior wall (diastolic 
thickness 8.5 mm, normal value 4-6 mm), reduced iastolic left 
ventricular function and mild pericardial effusion. Blood chem- 
istry showed normoglycaemia and severe metabolic acidosis 
(pH7.18, HCO3 8; lactate 15retool/i, reference value <2 
mmol/1; pyruvate 0.35 mmol/1, reference value < 0.16 mmol/1; 
lactate/pyruvate molar ratio 42; 3-hydroxybutyrate 0.55 mmol/ 
1, reference value < 0.06; acetoacetate 0.12 mmol/1, reference 
value < 0.02; 3-hydroxybutyrate/acetoacetate molar ratio 
4.58); urinary organic acid screening revealed increased excre- 
tion of lactic acid (4800 mmol/mol creatinine, reference < 200), 
2-hydroxybutyric a id (55 mmol/mol creatinine, reference < 2), 
3-hydroxybutyric a id (212 mmol/mol creatinine, reference <2), 
fumaric 134mmol/mol creatinine, reference <5),  malic 
(74mmol/mol creatinine, reference <5),  ct-ketoglutaric (165 
mmol/mol creatinine, reference <10), and citric acid (325 
mmol/mol creatinine, reference <20); serum total and free 
carnitine concentration were 56 and 44gmol/1, respectively; 
total CPK was 216U/1 (normal < 290) with normal CK-MB 
fraction. 
He received large doses of carnitine and sodium bicarbo- 
nate without clinical benefit. Because of increasing lactate 
levels (18 mmol/1) and clinical worsening, DCA (Tokyo Kasey, 
Japan) was administrated orally in three doses (150rag per 
Abbreviations: COX = cytochrome C oxidase; DCA =- di- 
chloroacetate 
day). After 3, 6, 9, 12 and 24h, blood lactate levels were 18 
and decreased to 12, 10, 6 and 1.8retool/i, respectively, and 
pyruvate from 0.37 to 0.14retool/i, then remained within the 
normal range although the dose of DCA was gradually de- 
creased to 25 ng/kg 15er day within 7 days. 
On the 2nd day of DCA therapy a muscle biopsy was per- 
formed and revealed reduced activity in COX (18.9 nmol/mird 
mg; control 63 + 29) and normal succinate cytochrome c reduc- 
tase, citrate synthase, NADH dehydrogenase, succinate de- 
hydrogenase and pyruvate dehydrogenase. After 16 days of 
oral administration of DCA, the drug was discontinued be- 
cause of the improved clinical condition; 12 h later, however, 
the lactate level again increased to 15 mmol/1 and remained 
between 14 and 18 mmol/1 until DCA administration was re- 
sumed; thereafter lactate levels decreased to normal levels 
within 2 days. Furthermore, thiamine (1 mg/kg/day) was added 
because DCA, stimulating two thiamine-dependent zymes 
(PDH and branched chain a-keto acid dehydrogenase com- 
plex), might induce a deficiency for this vitamin [3]. After 
9 months of therapy, there has been a dramatic reduction of 
heart size: echocardiography showed a normal heart, with 
normal wall thickness (5 mm; controls 4-6 ram) and left ven- 
tricular function (ejection fraction 76%, systolic fraction 43%) 
and low blood lactate values ranging from 1.6 to 3.1mmol/1. 
Because it is thought hat DCA is metabolised to oxalate and 
glyoxalate in liver we measured plasma oxalate which was nor- 
mal (5 gmol/1; controls < 7); The child is developing normally, 
both physically and mentally; EEG and auditory and somato- 
sensory evoked potentials are normal. 
Although experience with DCA therapy is still limited to 
few cases, this is the first patient with muscle COX deficiency 
who appears to have responded to this therapy. Two possible 
explanations can be proposed. The first is that COX deficiency 
in the child was due to a mitochondrial DNA defect, and mus- 
cle and liver had a mixture of normal and COX deficient 
mitochondria on the basis of heteroplasmy. If the proportion 
of normal mitochondria is adequate, activation of pyruvate 
dehydrogenase by DCA would stimulate degradation of lac- 
tate in peripheral tissues resulting in decreased lactic acidae- 
mia. The second explanation is that DCA may improve cardiac 
output and left ventricular mechanical efficiency under condi- 
tions of myocardial ischaemia [3], probably by favouring myo- 
cardial metabolism of carbohydrate and lactate over fat meta- 
bolism. 
Finally, to the best of our knowledge, there is no evidence 
that DCA should affect muscle COX activity in vivo (in vitro 
addition of drug does not alter COX activity in normal muscle; 
personal observation); only longitudinal studies comparing 
enzyme activities in muscle biopsies obtained before and dur- 
ing DCA treatment could answer this question directly. 
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